Dillon & Associates Inc Immunity Bio, Inc. Transaction History
Dillon & Associates Inc
- $778 Million
- Q3 2025
A detailed history of Dillon & Associates Inc transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Dillon & Associates Inc holds 25,800 shares of IBRX stock, worth $53,664. This represents 0.01% of its overall portfolio holdings.
Number of Shares
25,800
Previous 25,800
-0.0%
Holding current value
$53,664
Previous $77,000
32.47%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding IBRX
# of Institutions
299Shares Held
137MCall Options Held
2.59MPut Options Held
3.35M-
Vanguard Group Inc Valley Forge, PA27.7MShares$57.5 Million0.0% of portfolio
-
Jane Street Group, LLC New York, NY12.8MShares$26.7 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$23.8 Million0.0% of portfolio
-
State Street Corp Boston, MA11.3MShares$23.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.89MShares$14.3 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $833M
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...